Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Biotech Stock Moves Higher After Fast-Track Designation
01:36pm, Wednesday, 15'th Sep 2021
SAGE Therapeutics Inc (NYSE:SAGE) is in the spotlight today, after the drugmaker received fast-track designation from the U.S. Food and Drug Administration (FDA) for its potential Huntington's disease
Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington's Disease
06:30am, Wednesday, 15'th Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with d
Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
06:30am, Thursday, 02'nd Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
7 Best Biotech Stocks to Buy in 2021 with Huge Upside
12:08pm, Wednesday, 25'th Aug 2021
Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.
SAGE Therapeutics, Inc. (SAGE) CEO Barry Greene on Q2 2021 Results - Earnings Call Transcript
03:00pm, Tuesday, 03'rd Aug 2021
SAGE Therapeutics, Inc. (SAGE) CEO Barry Greene on Q2 2021 Results - Earnings Call Transcript
Sage Therapeutics Drops Two Zuranolone Depression Trials Deemed Unnecessary For Approval
12:46pm, Tuesday, 03'rd Aug 2021
Tucked in the Q2 earnings release, Sage Therapeutics Inc (NASDAQ: SAGE) has terminated two long-suspended Phase 3 zuranolone trials in major depressive disorder (MDD). What Happened: After talks wi
Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
06:30am, Tuesday, 03'rd Aug 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of peopl
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:05pm, Tuesday, 27'th Jul 2021
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
06:30am, Tuesday, 20'th Jul 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
02:04pm, Sunday, 11'th Jul 2021
Several drugmakers have important clinical trial updates on the way.
Sage Therapeutics to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
06:30am, Thursday, 08'th Jul 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
Sage Therapeutics to Participate in SVB Leerink's 3rd Annual CNS Forum
06:30am, Thursday, 24'th Jun 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
What Happened to Sage Therapeutics Stock?
06:21am, Monday, 21'st Jun 2021
Sage has been struggling for some time to bring its flagship antidepressant to the market.
Here's Why Sage Therapeutics Tanked This Week
07:00am, Saturday, 19'th Jun 2021
The neuroscience-focused biotech company didn't give investors the result they wanted.
4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List
04:36pm, Thursday, 17'th Jun 2021
Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.
